UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000027699
Receipt No. R000031730
Scientific Title The efficacy evaluation of the knee subjective symptoms and motor function by collagen containing drink
Date of disclosure of the study information 2017/06/09
Last modified on 2018/06/11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title The efficacy evaluation of the knee subjective symptoms and motor function by collagen containing drink
Acronym The efficacy evaluation of the knee subjective symptoms and motor function by collagen containing drink
Scientific Title The efficacy evaluation of the knee subjective symptoms and motor function by collagen containing drink
Scientific Title:Acronym The efficacy evaluation of the knee subjective symptoms and motor function by collagen containing drink
Region
Japan

Condition
Condition Healthy adult
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the efficacy of collagen containing drink on the knee subjective symptoms and motor function for 12 weeks.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes locomotive syndrome risk test, JKOM before and 6, 12 weeks after the intervention with the test drink
Key secondary outcomes JOA, levels of change in knee joint stiffness, VAS, handgrip before and 6, 12 weeks after the intervention with the test drink

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 Collagen containing drink are ingested for 12 consecutive weeks
Interventions/Control_2 Collagen free drink are ingested for 12 consecutive weeks
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
40 years-old <=
Age-upper limit
74 years-old >=
Gender Male and Female
Key inclusion criteria (1)Males and females at the ages of 40 to 74
(2)Subjects who are judged as stage 1 in locomotive syndrome risk test
(3)Subjects who confirmed pain of knee joint by JKOM and VAS
(4)Subjects who are classified into 0-I grade on the basis of the Kellgren-Lawrence classification. (Subjects who undiagnosed with Knee Osteoarthritis by physician)
Key exclusion criteria (1)Subjects who exceeded the value of knee pain on JKOM, question-I : the degree of pain, more than the sum VAS value of other joint pain (e.g., ankle, elbow, finger, shoulder, back and hip)
(2)Subjects who are confirmed 30-points by JOA score, the degree of knee pain and walk ability
(3)Subjects who are suspected gouty attack with hyperuricemia
(4)Subjects who have positive rheumatoid factors on the screening test or may have rheumatic pain
(5)Subjects who have performed arthroplasty or need it
(6)Subjects who regularly take health food containing bone, joint, muscle wellness from three month before the screening test to the end of the study
(7)Subjects who regularly take medicine
(8)Subjects who have been performed intra-articular hyaluronic acid or steroid drug injection within a year before the screening test
(9)Subjects who get an intense exercise to make excessive load on the joints
(10)Subjects who have a history of the disorder related to bone and joint such as fracture and sprain within a year before the screening test
(11)Subjects who regularly use a stick or supporter
(12)Subjects who routinely exert an influence on the efficacy evaluation
(13)Subjects who get a diagnosis of malignancy, are under treatment for hypertension, cardiac disease, renal disease and thyroid dysfunction, and have a history of serious disorder such as hepatic disease
(14)Subjects who consume an excess amounts of alcohol
(15)Subjects who have possibility of allergy symptoms onset by the test supplement
(16)Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire
(17)Subjects who have participated in other clinical study within a month before the screening test or who intend to participate in study period
(18)Subjects who intend to become pregnant or lactating
(19)Subjects who are judged as unsuitable for this study by physician
Target sample size 30

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Sadao Mori
Organization Morinaga & Co.,Ltd
Division name Health and Wellness Headquarters
Zip code
Address 2-1-1, Shimodueyoshi, Tsurumi-ku, Yokohama
TEL 070-3864-8266
Email s-mori-ab@morinaga.co.jp

Public contact
Name of contact person
1st name
Middle name
Last name Noriko Watanabe
Organization TTC Co.,Ltd
Division name Clinical Research Planning Department
Zip code
Address Seibu Shinkin Bank Ebisu Bldg.,1-20-2, Ebisunishi, Shibuya-ku, Tokyo
TEL 03-5459-5329
Homepage URL
Email n.watanabe@ttc-tokyo.co.jp

Sponsor
Institute TTC Co.,Ltd
Institute
Department

Funding Source
Organization Morinaga & Co.,Ltd
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2017 Year 06 Month 09 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2017 Year 05 Month 25 Day
Date of IRB
Anticipated trial start date
2017 Year 06 Month 12 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 06 Month 09 Day
Last modified on
2018 Year 06 Month 11 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031730

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.